lpa Search Results


93
Alomone Labs lpar6
Figure 2. Co-localization of the gintonin (GT)-binding site with the LPA4 receptor subtype and a selective reduction in LPA4 receptor subtype expression levels in patients with AD. (A) Representative confocal images of the LPA receptor subtypes (LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, and <t>LPAR6;</t> green) and GT (red) in the cortices of the HCs and patients with AD. Scale bar = 200 µm. The insert images focus on the co-localization between gintonin (GT) and the LAP receptor subtypes. Scale bar = 100 µm. (B) Quantitative analysis of the co-localization between the GT and LPA receptor subtypes. (C–F) Western blot analysis of the LPA receptor subtypes in brain tissue from the HCs and patients with AD. The results indicate a significant decrease in LPAR4 expression in patients with AD, whereas no significant differences were observed for the other LPA receptor subtypes. Statistical significance was determined using a t-test. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01. Original Western blot images can be found in Figure S1.
Lpar6, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lpa/Anti-LPAR6+(P2RY5)+(extracellular)+Antibody/pm40001482-69-29-32
Average 93 stars, based on 1 article reviews
lpar6 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Croda International Plc 1 stearoyl 2 hydroxy sn glycero 3 phosphate
Figure 2. Co-localization of the gintonin (GT)-binding site with the LPA4 receptor subtype and a selective reduction in LPA4 receptor subtype expression levels in patients with AD. (A) Representative confocal images of the LPA receptor subtypes (LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, and <t>LPAR6;</t> green) and GT (red) in the cortices of the HCs and patients with AD. Scale bar = 200 µm. The insert images focus on the co-localization between gintonin (GT) and the LAP receptor subtypes. Scale bar = 100 µm. (B) Quantitative analysis of the co-localization between the GT and LPA receptor subtypes. (C–F) Western blot analysis of the LPA receptor subtypes in brain tissue from the HCs and patients with AD. The results indicate a significant decrease in LPAR4 expression in patients with AD, whereas no significant differences were observed for the other LPA receptor subtypes. Statistical significance was determined using a t-test. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01. Original Western blot images can be found in Figure S1.
1 Stearoyl 2 Hydroxy Sn Glycero 3 Phosphate, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lpa/16%3A0+LPA/pmc03418163-153-14-26
Average 94 stars, based on 1 article reviews
1 stearoyl 2 hydroxy sn glycero 3 phosphate - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
OriGene ta310972 antiapo a rabbit monoclonal antibody
Figure 2. Co-localization of the gintonin (GT)-binding site with the LPA4 receptor subtype and a selective reduction in LPA4 receptor subtype expression levels in patients with AD. (A) Representative confocal images of the LPA receptor subtypes (LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, and <t>LPAR6;</t> green) and GT (red) in the cortices of the HCs and patients with AD. Scale bar = 200 µm. The insert images focus on the co-localization between gintonin (GT) and the LAP receptor subtypes. Scale bar = 100 µm. (B) Quantitative analysis of the co-localization between the GT and LPA receptor subtypes. (C–F) Western blot analysis of the LPA receptor subtypes in brain tissue from the HCs and patients with AD. The results indicate a significant decrease in LPAR4 expression in patients with AD, whereas no significant differences were observed for the other LPA receptor subtypes. Statistical significance was determined using a t-test. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01. Original Western blot images can be found in Figure S1.
Ta310972 Antiapo A Rabbit Monoclonal Antibody, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lpa/Lipoprotein+a+(LPA)+Rabbit+Monoclonal+Antibody/pmc09018215__hcg___15___e003489___s001-62-9-14
Average 90 stars, based on 1 article reviews
ta310972 antiapo a rabbit monoclonal antibody - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
MedChemExpress oleoyl lpa
Figure 2. Co-localization of the gintonin (GT)-binding site with the LPA4 receptor subtype and a selective reduction in LPA4 receptor subtype expression levels in patients with AD. (A) Representative confocal images of the LPA receptor subtypes (LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, and <t>LPAR6;</t> green) and GT (red) in the cortices of the HCs and patients with AD. Scale bar = 200 µm. The insert images focus on the co-localization between gintonin (GT) and the LAP receptor subtypes. Scale bar = 100 µm. (B) Quantitative analysis of the co-localization between the GT and LPA receptor subtypes. (C–F) Western blot analysis of the LPA receptor subtypes in brain tissue from the HCs and patients with AD. The results indicate a significant decrease in LPAR4 expression in patients with AD, whereas no significant differences were observed for the other LPA receptor subtypes. Statistical significance was determined using a t-test. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01. Original Western blot images can be found in Figure S1.
Oleoyl Lpa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lpa/1-Oleoyl+lysophosphatidic+acid/pmc05207162-324-31-38
Average 93 stars, based on 1 article reviews
oleoyl lpa - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Alomone Labs anti lpa1
Figure 2. Co-localization of the gintonin (GT)-binding site with the LPA4 receptor subtype and a selective reduction in LPA4 receptor subtype expression levels in patients with AD. (A) Representative confocal images of the LPA receptor subtypes (LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, and <t>LPAR6;</t> green) and GT (red) in the cortices of the HCs and patients with AD. Scale bar = 200 µm. The insert images focus on the co-localization between gintonin (GT) and the LAP receptor subtypes. Scale bar = 100 µm. (B) Quantitative analysis of the co-localization between the GT and LPA receptor subtypes. (C–F) Western blot analysis of the LPA receptor subtypes in brain tissue from the HCs and patients with AD. The results indicate a significant decrease in LPAR4 expression in patients with AD, whereas no significant differences were observed for the other LPA receptor subtypes. Statistical significance was determined using a t-test. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01. Original Western blot images can be found in Figure S1.
Anti Lpa1, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lpa/Anti-LPAR1+(EDG2)+(extracellular)+Antibody/pmc09120792-46-7-13
Average 94 stars, based on 1 article reviews
anti lpa1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
Alomone Labs anti lpa3 alr 033
Figure 2. Co-localization of the gintonin (GT)-binding site with the LPA4 receptor subtype and a selective reduction in LPA4 receptor subtype expression levels in patients with AD. (A) Representative confocal images of the LPA receptor subtypes (LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, and <t>LPAR6;</t> green) and GT (red) in the cortices of the HCs and patients with AD. Scale bar = 200 µm. The insert images focus on the co-localization between gintonin (GT) and the LAP receptor subtypes. Scale bar = 100 µm. (B) Quantitative analysis of the co-localization between the GT and LPA receptor subtypes. (C–F) Western blot analysis of the LPA receptor subtypes in brain tissue from the HCs and patients with AD. The results indicate a significant decrease in LPAR4 expression in patients with AD, whereas no significant differences were observed for the other LPA receptor subtypes. Statistical significance was determined using a t-test. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01. Original Western blot images can be found in Figure S1.
Anti Lpa3 Alr 033, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lpa/Anti-LPAR3+(EDG7)+(extracellular)+Antibody/pm27605627-94-60-63
Average 90 stars, based on 1 article reviews
anti lpa3 alr 033 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Proteintech lpar3 proteintech 19509 1 ap
Figure 2. Co-localization of the gintonin (GT)-binding site with the LPA4 receptor subtype and a selective reduction in LPA4 receptor subtype expression levels in patients with AD. (A) Representative confocal images of the LPA receptor subtypes (LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, and <t>LPAR6;</t> green) and GT (red) in the cortices of the HCs and patients with AD. Scale bar = 200 µm. The insert images focus on the co-localization between gintonin (GT) and the LAP receptor subtypes. Scale bar = 100 µm. (B) Quantitative analysis of the co-localization between the GT and LPA receptor subtypes. (C–F) Western blot analysis of the LPA receptor subtypes in brain tissue from the HCs and patients with AD. The results indicate a significant decrease in LPAR4 expression in patients with AD, whereas no significant differences were observed for the other LPA receptor subtypes. Statistical significance was determined using a t-test. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01. Original Western blot images can be found in Figure S1.
Lpar3 Proteintech 19509 1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lpa/EDG7-Specific+Antibody/ppr0694844-112-34-35
Average 93 stars, based on 1 article reviews
lpar3 proteintech 19509 1 ap - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Croda International Plc lpa
Figure 2. Co-localization of the gintonin (GT)-binding site with the LPA4 receptor subtype and a selective reduction in LPA4 receptor subtype expression levels in patients with AD. (A) Representative confocal images of the LPA receptor subtypes (LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, and <t>LPAR6;</t> green) and GT (red) in the cortices of the HCs and patients with AD. Scale bar = 200 µm. The insert images focus on the co-localization between gintonin (GT) and the LAP receptor subtypes. Scale bar = 100 µm. (B) Quantitative analysis of the co-localization between the GT and LPA receptor subtypes. (C–F) Western blot analysis of the LPA receptor subtypes in brain tissue from the HCs and patients with AD. The results indicate a significant decrease in LPAR4 expression in patients with AD, whereas no significant differences were observed for the other LPA receptor subtypes. Statistical significance was determined using a t-test. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01. Original Western blot images can be found in Figure S1.
Lpa, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lpa/C18%3A1+LPA/pmc06443858-24-2-6
Average 94 stars, based on 1 article reviews
lpa - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

92
Cusabio human lpa elisa kits
Figure 2. Co-localization of the gintonin (GT)-binding site with the LPA4 receptor subtype and a selective reduction in LPA4 receptor subtype expression levels in patients with AD. (A) Representative confocal images of the LPA receptor subtypes (LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, and <t>LPAR6;</t> green) and GT (red) in the cortices of the HCs and patients with AD. Scale bar = 200 µm. The insert images focus on the co-localization between gintonin (GT) and the LAP receptor subtypes. Scale bar = 100 µm. (B) Quantitative analysis of the co-localization between the GT and LPA receptor subtypes. (C–F) Western blot analysis of the LPA receptor subtypes in brain tissue from the HCs and patients with AD. The results indicate a significant decrease in LPAR4 expression in patients with AD, whereas no significant differences were observed for the other LPA receptor subtypes. Statistical significance was determined using a t-test. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01. Original Western blot images can be found in Figure S1.
Human Lpa Elisa Kits, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lpa/Human+lysophosphatidic+acid+(LPA)+Elisa+kit/pm29927323-89-23-33
Average 92 stars, based on 1 article reviews
human lpa elisa kits - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

93
Proteintech lpa1 antibody
<t>LPA1</t> is required for AM966-induced phosphorylation of VE-cadherin. (a) HLMVECs (~70% confluent) were transfected with LPA1 siRNA (siLPA1) or control (sicont) for 72 h, and then cells were treated with AM966 (1.0 μ M) for 30 min. Cell lysates were immunoblotted with P-VE-cadherin, total VE-cadherin, and LPA1 antibodies. (b) Analysis of P-VE-cadherin by densitometry of the results in (a) was performed by Image J software ( n = 3), and statistical analysis was shown. (c) HLMVECs (~70% confluent) were transfected with minigenes encoding G α 12 or G α 13 peptide for 24 h, and then cells were treated with AM966 (1.0 μ M) for 30 min. Cell lysates were immunoblotted with P-VE-cadherin and total VE-cadherin antibodies. (d) Analysis of P-VE-cadherin by densitometry of the results in (c) was performed by Image J software ( n = 3), and statistical analysis was shown. Shown are representative blots from three independent experiments. (e) HLMVECs (~70% confluent) transfected with LPA1 siRNA (siLPA1) or control (sicont) were plated on gold microelectrodes and then cells were treated with AM966 (1.0 μ M) or DMSO. The TEER tracing represents pooled data (±SEM) from 3 independent experiments. (f) The resistance in response to AM966 treatments during indicated time period (e) was quantified and statistical analysis was performed.
Lpa1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lpa/EDG2+Antibody/pmc05350330-36-0-5
Average 93 stars, based on 1 article reviews
lpa1 antibody - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Croda International Plc lysophosphatidic acid 857228
<t>LPA1</t> is required for AM966-induced phosphorylation of VE-cadherin. (a) HLMVECs (~70% confluent) were transfected with LPA1 siRNA (siLPA1) or control (sicont) for 72 h, and then cells were treated with AM966 (1.0 μ M) for 30 min. Cell lysates were immunoblotted with P-VE-cadherin, total VE-cadherin, and LPA1 antibodies. (b) Analysis of P-VE-cadherin by densitometry of the results in (a) was performed by Image J software ( n = 3), and statistical analysis was shown. (c) HLMVECs (~70% confluent) were transfected with minigenes encoding G α 12 or G α 13 peptide for 24 h, and then cells were treated with AM966 (1.0 μ M) for 30 min. Cell lysates were immunoblotted with P-VE-cadherin and total VE-cadherin antibodies. (d) Analysis of P-VE-cadherin by densitometry of the results in (c) was performed by Image J software ( n = 3), and statistical analysis was shown. Shown are representative blots from three independent experiments. (e) HLMVECs (~70% confluent) transfected with LPA1 siRNA (siLPA1) or control (sicont) were plated on gold microelectrodes and then cells were treated with AM966 (1.0 μ M) or DMSO. The TEER tracing represents pooled data (±SEM) from 3 independent experiments. (f) The resistance in response to AM966 treatments during indicated time period (e) was quantified and statistical analysis was performed.
Lysophosphatidic Acid 857228, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lpa/C18+LPA/pmc06195446-530-20-31
Average 90 stars, based on 1 article reviews
lysophosphatidic acid 857228 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
TargetMol lp a
Figure 3. <t>Lp(a)</t> stimulation <t>of</t> <t>VICs</t> results in a PFKFB3-dependent increase in glycolysis. 2
Lp A, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lpa/Anti-Apolipoprotein+A+Antibody/10__1093_slash_ehjopen_slash_oeaf068-127-9-19
Average 93 stars, based on 1 article reviews
lp a - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


Figure 2. Co-localization of the gintonin (GT)-binding site with the LPA4 receptor subtype and a selective reduction in LPA4 receptor subtype expression levels in patients with AD. (A) Representative confocal images of the LPA receptor subtypes (LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, and LPAR6; green) and GT (red) in the cortices of the HCs and patients with AD. Scale bar = 200 µm. The insert images focus on the co-localization between gintonin (GT) and the LAP receptor subtypes. Scale bar = 100 µm. (B) Quantitative analysis of the co-localization between the GT and LPA receptor subtypes. (C–F) Western blot analysis of the LPA receptor subtypes in brain tissue from the HCs and patients with AD. The results indicate a significant decrease in LPAR4 expression in patients with AD, whereas no significant differences were observed for the other LPA receptor subtypes. Statistical significance was determined using a t-test. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01. Original Western blot images can be found in Figure S1.

Journal: Biomolecules

Article Title: Gintonin Binds to Reduced LPA4 Receptor Subtype in Human Cortical Neurons in Alzheimer's Disease Brains.

doi: 10.3390/biom15020179

Figure Lengend Snippet: Figure 2. Co-localization of the gintonin (GT)-binding site with the LPA4 receptor subtype and a selective reduction in LPA4 receptor subtype expression levels in patients with AD. (A) Representative confocal images of the LPA receptor subtypes (LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, and LPAR6; green) and GT (red) in the cortices of the HCs and patients with AD. Scale bar = 200 µm. The insert images focus on the co-localization between gintonin (GT) and the LAP receptor subtypes. Scale bar = 100 µm. (B) Quantitative analysis of the co-localization between the GT and LPA receptor subtypes. (C–F) Western blot analysis of the LPA receptor subtypes in brain tissue from the HCs and patients with AD. The results indicate a significant decrease in LPAR4 expression in patients with AD, whereas no significant differences were observed for the other LPA receptor subtypes. Statistical significance was determined using a t-test. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01. Original Western blot images can be found in Figure S1.

Article Snippet: The primary antibodies used were LPAR1 (1:2000, ALR031, Alomone Labs), LPAR2 (1:2000, ALR-032, Alomone Labs), LPAR3 (1:2000, ab23692, Abcam), LPAR4 (1:2000, ALR-034, Alomone Labs), LPAR5 (1:2000, ALR-035, Alomone Labs), LPAR6 (1:2000, ALR-036, Alomone labs), and β-actin (1:2000, 3700s, CST).

Techniques: Binding Assay, Expressing, Confocal, Analysis, Western Blot, Tissue

LPA1 is required for AM966-induced phosphorylation of VE-cadherin. (a) HLMVECs (~70% confluent) were transfected with LPA1 siRNA (siLPA1) or control (sicont) for 72 h, and then cells were treated with AM966 (1.0 μ M) for 30 min. Cell lysates were immunoblotted with P-VE-cadherin, total VE-cadherin, and LPA1 antibodies. (b) Analysis of P-VE-cadherin by densitometry of the results in (a) was performed by Image J software ( n = 3), and statistical analysis was shown. (c) HLMVECs (~70% confluent) were transfected with minigenes encoding G α 12 or G α 13 peptide for 24 h, and then cells were treated with AM966 (1.0 μ M) for 30 min. Cell lysates were immunoblotted with P-VE-cadherin and total VE-cadherin antibodies. (d) Analysis of P-VE-cadherin by densitometry of the results in (c) was performed by Image J software ( n = 3), and statistical analysis was shown. Shown are representative blots from three independent experiments. (e) HLMVECs (~70% confluent) transfected with LPA1 siRNA (siLPA1) or control (sicont) were plated on gold microelectrodes and then cells were treated with AM966 (1.0 μ M) or DMSO. The TEER tracing represents pooled data (±SEM) from 3 independent experiments. (f) The resistance in response to AM966 treatments during indicated time period (e) was quantified and statistical analysis was performed.

Journal: Mediators of Inflammation

Article Title: AM966, an Antagonist of Lysophosphatidic Acid Receptor 1, Increases Lung Microvascular Endothelial Permeability through Activation of Rho Signaling Pathway and Phosphorylation of VE-Cadherin

doi: 10.1155/2017/6893560

Figure Lengend Snippet: LPA1 is required for AM966-induced phosphorylation of VE-cadherin. (a) HLMVECs (~70% confluent) were transfected with LPA1 siRNA (siLPA1) or control (sicont) for 72 h, and then cells were treated with AM966 (1.0 μ M) for 30 min. Cell lysates were immunoblotted with P-VE-cadherin, total VE-cadherin, and LPA1 antibodies. (b) Analysis of P-VE-cadherin by densitometry of the results in (a) was performed by Image J software ( n = 3), and statistical analysis was shown. (c) HLMVECs (~70% confluent) were transfected with minigenes encoding G α 12 or G α 13 peptide for 24 h, and then cells were treated with AM966 (1.0 μ M) for 30 min. Cell lysates were immunoblotted with P-VE-cadherin and total VE-cadherin antibodies. (d) Analysis of P-VE-cadherin by densitometry of the results in (c) was performed by Image J software ( n = 3), and statistical analysis was shown. Shown are representative blots from three independent experiments. (e) HLMVECs (~70% confluent) transfected with LPA1 siRNA (siLPA1) or control (sicont) were plated on gold microelectrodes and then cells were treated with AM966 (1.0 μ M) or DMSO. The TEER tracing represents pooled data (±SEM) from 3 independent experiments. (f) The resistance in response to AM966 treatments during indicated time period (e) was quantified and statistical analysis was performed.

Article Snippet: LPA1 antibody was obtained from Proteintech.

Techniques: Phospho-proteomics, Transfection, Control, Software

AM966-induced phosphorylation of VE-cadherin is not FAK-dependent. (a) HLMVECs (~70% confluent) transfected with siLPA1 or sicont were treated with AM966 (1.0 μ M) or DMSO for 30 min. Cell lysates were immunoblotted with phosphospecific FAK (P-FAK), total FAK, and LPA1 antibodies. (b) Analysis of P-FAK by densitometry of the results in (a) was performed by Image J software ( n = 3), and statistical analysis was shown. (c) Confluent HLMVECs were pretreated with FAK kinase inhibitor (0 to 10.0 μ M) for 1 h, and then cells were treated with DMSO or AM966 (1.0 μ M) for an additional 30 min. Cell lysates were immunoblotted with P-VE-cadherin and total VE-cadherin antibodies. (d) Analysis of P-VE-cadherin by densitometry of the results in (c) was performed by Image J software ( n = 3), and statistical analysis was shown. Shown are representative blots from three independent experiments. (e) Confluent HLMVECs were plated on gold microelectrodes and pretreated with FAK inhibitor (1.0 or 5.0 μ M) for 1 h and then stimulated by 1.0 μ M AM966 or DMSO. The TEER tracing represents pooled data (±SEM) from 3 independent experiments. (f) The resistance in response to AM966 treatments during indicated time period (e) was quantified and statistical analysis was performed.

Journal: Mediators of Inflammation

Article Title: AM966, an Antagonist of Lysophosphatidic Acid Receptor 1, Increases Lung Microvascular Endothelial Permeability through Activation of Rho Signaling Pathway and Phosphorylation of VE-Cadherin

doi: 10.1155/2017/6893560

Figure Lengend Snippet: AM966-induced phosphorylation of VE-cadherin is not FAK-dependent. (a) HLMVECs (~70% confluent) transfected with siLPA1 or sicont were treated with AM966 (1.0 μ M) or DMSO for 30 min. Cell lysates were immunoblotted with phosphospecific FAK (P-FAK), total FAK, and LPA1 antibodies. (b) Analysis of P-FAK by densitometry of the results in (a) was performed by Image J software ( n = 3), and statistical analysis was shown. (c) Confluent HLMVECs were pretreated with FAK kinase inhibitor (0 to 10.0 μ M) for 1 h, and then cells were treated with DMSO or AM966 (1.0 μ M) for an additional 30 min. Cell lysates were immunoblotted with P-VE-cadherin and total VE-cadherin antibodies. (d) Analysis of P-VE-cadherin by densitometry of the results in (c) was performed by Image J software ( n = 3), and statistical analysis was shown. Shown are representative blots from three independent experiments. (e) Confluent HLMVECs were plated on gold microelectrodes and pretreated with FAK inhibitor (1.0 or 5.0 μ M) for 1 h and then stimulated by 1.0 μ M AM966 or DMSO. The TEER tracing represents pooled data (±SEM) from 3 independent experiments. (f) The resistance in response to AM966 treatments during indicated time period (e) was quantified and statistical analysis was performed.

Article Snippet: LPA1 antibody was obtained from Proteintech.

Techniques: Phospho-proteomics, Transfection, Software

AM966 reduces pulmonary microvascular cell barrier integrity through LPA1/G α 12/13-mediated phosphorylation of MLC and VE-cadherin. AM966 is ligated to LPA1 and triggers RhoA/Rho kinase pathway, thereby increasing MLC phosphorylation and cytoskeletal rearrangement. AM966 induces phosphorylation of VE-cadherin. Therefore, AM966 increases lung endothelial permeability.

Journal: Mediators of Inflammation

Article Title: AM966, an Antagonist of Lysophosphatidic Acid Receptor 1, Increases Lung Microvascular Endothelial Permeability through Activation of Rho Signaling Pathway and Phosphorylation of VE-Cadherin

doi: 10.1155/2017/6893560

Figure Lengend Snippet: AM966 reduces pulmonary microvascular cell barrier integrity through LPA1/G α 12/13-mediated phosphorylation of MLC and VE-cadherin. AM966 is ligated to LPA1 and triggers RhoA/Rho kinase pathway, thereby increasing MLC phosphorylation and cytoskeletal rearrangement. AM966 induces phosphorylation of VE-cadherin. Therefore, AM966 increases lung endothelial permeability.

Article Snippet: LPA1 antibody was obtained from Proteintech.

Techniques: Phospho-proteomics, Permeability

Figure 3. Lp(a) stimulation of VICs results in a PFKFB3-dependent increase in glycolysis. 2

Journal: European Heart Journal Open

Article Title: Fueling Stenosis: The integral role of PFKFB3-mediated glycolysis in Lp(a)-induced Valve Inflammation

doi: 10.1093/ehjopen/oeaf068

Figure Lengend Snippet: Figure 3. Lp(a) stimulation of VICs results in a PFKFB3-dependent increase in glycolysis. 2

Article Snippet: After 2 days, VICs were stimulated overnight with 100mg/dl Lp(a) with or 10 without 5μM KAN0438757 (K-757) acquired from TargetMol EU GmbH (Linz, Austria).

Techniques: